Clinical evaluation of pimecrolimus eye drops for treatment of canine keratoconjunctivitis sicca: A comparison with cyclosporine A

Veterinary Journal

Volumn 179, Issue 1, 2009, Pages 70-77

  Ofri, Ron ^a   Lambrou, George N ^b,c   Allgoewer, Ingrid ^d   Graenitz, Uwe ^e   Pena, Teresa M ^f   Spiess, Bernhard M ^g   Latour, Elisabeth ^b  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b NOVARTIS PHARMA AG   (Switzerland)

^c UNIVERSITÉ DE STRASBOURG   (France)

^d Veterinary Ophthalmology Clinic   (Germany)

^e Veterinary Ophthalmology Clinic   (Germany)

^f UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^g UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Cyclosporine A; Dog; Dry eye; Keratoconjunctivitis sicca; Pimecrolimus

Indexed keywords

CYCLOSPORIN A; OPTIMMUNE; PIMECROLIMUS; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CLINICAL EVALUATION; CLINICAL FEATURE; CONTROLLED STUDY; DOG DISEASE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEMALE; KERATOCONJUNCTIVITIS SICCA; MALE; NONHUMAN; SCHIRMER TEST;

ADMINISTRATION, TOPICAL; ANIMALS; CYCLOSPORINE; DOG DISEASES; DOGS; FEMALE; IMMUNOSUPPRESSIVE AGENTS; KERATOCONJUNCTIVITIS SICCA; MALE; OPHTHALMIC SOLUTIONS; TACROLIMUS; TREATMENT OUTCOME;

CANIS FAMILIARIS;

EID: 56849105928     PISSN: 10900233     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tvjl.2007.08.034     Document Type: Article

References (27)

1. Berdoulay A., English R.V., and Nadelstein B. Effect of topical 0.02% tacrolimus aqueous suspension on tear production in dogs with keratoconjunctivitis sicca. Veterinary Ophthalmology 8 (2005) 225-232
2. Bounous D.I., Carmichael K.P., Kaswan R.L., Hirsh S., and Stiles J. Effects of ophthalmic cyclosporine on lacrimal gland pathology and function in dogs with keratoconjunctivitis sicca. Veterinary and Comparative Ophthalmology 5 (1995) 5-14
3. Eichenfield L.F., and Beck L. Elidel (pimecrolimus) cream 1%: a nonsteroidal topical agent for the treatment of atopic dermatitis. Journal of Allergy and Clinical Immunology 111 (2003) 1153-1168
4. Grassberger M., Baumruker T., Enz A., Hiestand P., Hultsch T., Kalthoff F., Schuler W., Schulz M., Werner F.J., Winiski A., Wolff B., and Zenke G. A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. British Journal of Dermatology 141 (1999) 264-273
5. Helper L.C. The tear film in the dog. Causes and treatment of diseases associated with overproduction and underproduction of tears. Animal Eye Research 15 (1996) 5-11
6. Kalthoff F.S., Chung J., and Stuetz A. Pimecrolimus inhibits up-regulation of OX40 and synthesis of inflammatory cytokines upon secondary T cell activation by allogeneic dendritic cells. Clinical and Experimental Immunology 130 (2002) 85-92
7. Kaswan R.L., Martin C.L., and Dawe D.L. Rheumatoid factor determination of 50 dogs with keratoconjunctivitis sicca. Journal of the American Veterinary Medical Association 183 (1983) 1073-1075
8. Kaswan R.L., Martin C.L., and Chapman Jr. W.L. Keratoconjunctivitis sicca: histopathologic study of nictitating membrane and lacrimal glands from 28 dogs. American Journal of Veterinary Research 45 (1984) 112-118
9. Kaswan R.L., Martin C.L., and Dawe D.L. Keratoconjunctivitis sicca: immunological evaluation of 62 canine cases. American Journal of Veterinary Research 46 (1985) 376-383
10. Kaswan R.L., Salisbury M.A., and Lothrup C.D. Interaction of age and gender on occurrence of canine keratoconjunctivitis sicca. Progress in Veterinary and Comparative Ophthalmology 1 (1991) 93-97
11. McCarty C.A., Bansal A.K., Livingston P.M., Stanislavsky Y.L., and Taylor H.R. The epidemiology of dry eye in Melbourne, Australia. Ophthalmology 105 (1998) 1114-1119
12. Meingassner J.G., Grassberger M., Fahrngruber H., Moore H.D., Schuurman H., and Stutz A. A novel anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: in vivo pharmacology. British Journal of Dermatology 137 (1997) 568-576
13. Meingassner J.G., Fahrngruber H., and Bavandi A. Pimecrolimus inhibits the elicitation phase but does not suppress the sensitization phase in murine contact hypersensitivity, in contrast to tacrolimus and cyclosporine A. Journal of Investigative Dermatology 121 (2003) 77-80
14. Montes-Mico R., Caliz A., and Alio J.L. Changes in ocular aberrations after instillation of artificial tears in dry-eye patients. Journal of Cataract and Refractive Surgery 30 (2004) 1649-1652
15. Moore C.P. Diseases and surgery of the lacrimal secretory system. In: Gelatt K.N. (Ed). Veterinary Ophthalmology. third ed. (1999), Lippincott Williams & Wilkins, Philadelphia PA, USA 583-607
16. Morgan R.V., and Abrams K.L. Topical administration of cyclosporine for treatment of keratoconjunctivitis sicca in dogs. Journal of the American Veterinary Medical Association 199 (1991) 1043-1046
17. Moss S.E., Klein R., and Klein B.E. Prevalence of and risk factors for dry eye syndrome. Archives of Ophthalmology 118 (2000) 1264-1268
18. Nell B., Walde I., Billich A., Vit P., and Meingassner J.G. The effect of topical pimecrolimus on keratoconjunctivitis sicca and chronic superficial keratitis in dogs: results from an exploratory study. Veterinary Ophthalmology 8 (2005) 39-46
19. Olivero D.K., Davidson M.G., English R.V., Nasisse M.P., Jamieson V.E., and Gerig T.M. Clinical evaluation of 1% cyclosporine for topical treatment of keratoconjunctivitis sicca in dogs. Journal of the American Veterinary Medical Association 199 (1991) 1039-1042
20. Pflugfelder S.C., Wilhelmus K.R., Osato M.S., Matoba A.Y., and Font R.L. The autoimmune nature of aqueous tear deficiency. Ophthalmology 93 (1986) 1513-1517
21. Pflugfelder S.C., Jones D., Ji Z., Afonso A., and Monroy D. Altered cytokine balance in the tear fluid and conjunctiva of patients with Sjögren's syndrome keratoconjunctivitis sicca. Current Eye Research 19 (1999) 201-211
22. Rappersberger K., Komar M., Ebelin M.E., Scott G., Burtin P., Greig G., Kehren J., Chibout S.D., Cordier A., Holter W., Richter L., Oberbauer R., Stuetz A., and Wolff K. Pimecrolimus identifies a common genomic anti-inflammatory profile, is clinically highly effective in psoriasis and is well tolerated. Journal of Investigative Dermatology 119 (2002) 876-887
23. Sall K., Stevenson D., Mundorf T.K., and Reis B.L. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. Ophthalmology 107 (2000) 631-639
24. Sansom J., Barnett K.C., Neumann W., Schulte-Neumann A., Clerc B., Jegou J.P., de Haas V., and Weingarten A. Treatment of keratoconjunctivitis sicca in dogs with cyclosporine ophthalmic ointment: a European clinical field trial. Veterinary Record 137 (1995) 504-507
25. Schaumberg D.A., Sullivan D.A., Buring J.E., and Dana M.R. Prevalence of dry eye syndrome among US women. American Journal of Ophthalmology 136 (2003) 318-326
26. Stevenson D., Tauber J., and Reis B.L. Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The cclosporin A phase 2 study group. Ophthalmology 107 (2000) 967-974
27. Wolff K., and Stuetz A. Pimecrolimus for the treatment of inflammatory skin disease. Expert Opinion on Pharmacotherapy 5 (2004) 643-655